Monday, April 20, 2009

The Tragedy of Supremely Bad Law

"The press hailed it as a victory for patients. People harmed by drugs can sue the manufacturers, the Supreme Court recently ruled, even when the firms have scrupulously complied with all FDA rules.

But the decision will prove to be a pyrrhic victory for patients. In the long run it will hurt countless thousands desperately needing innovative drug treatments.

In dissent, Justice Samuel Alito pointed out that the case, Wyeth v. Levine "illustrates that tragic facts make bad law." The tragedy was that Diana Levine, a musician in Vermont, lost her arm due to gangrene after a physician's assistant injected her with Phenergan, an anti-nausea drug made by Wyeth that's been on the market since 1955. The assistant ignored no fewer than six warnings on the drug's FDA-approved label, stating that injection into an artery could cause gangrene and that the use of an IV heightened the risk of mis-injection. (The assistant also injected twice the maximum labeled dosage and ignored Levine's complaints of extreme pain, which the label stated indicated injection into an artery.)

Wyeth argued that it should not be liable to state tort actions when its label clearly and succinctly warned about the dangers of misuse in language approved by the FDA, the agency charged by federal law with determining the safety of drugs marketed to the American public. A Vermont jury awarded Levine $7.4 million.

In affirming that decision, the Supreme Court has opened up pharmaceutical companies to being whipsawed "with 50 (or more) potentially conflicting rules," Alito noted. In effect, the ruling leaves tort juries in every state "rather than the FDA...ultimately responsible for regulating warning labels for prescription drugs."

The Supreme Court's decision will inevitably lead pharmaceutical firms to pull drugs off the market, particularly those developed for relatively small populations of sufferers. The risk of tort liability suits in 50 different states will be too great to keep selling many of them. And that risk, no doubt, will stifle the development of new drugs for a wide variety of diseases."


Excerpts from an article by Hans A. von Spakovsky. Mr Spakovsky is a former commissioner on the Federal Election Commission and counsel to the assistant attorney general for civil rights at the Department of Justice.

No comments: